cinobufotalin has been researched along with Nasopharyngeal Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Z; Fang, W; Jiang, Q; Li, L; Li, X; Lin, X; Liu, C; Liu, X; Liu, Y; Liu, Z; Tang, Z; Xie, Y; Zhao, M; Zhou, J | 1 |
1 other study(ies) available for cinobufotalin and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway.
Topics: beta Catenin; Bufanolides; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Glycogen Synthase; Herpesvirus 4, Human; Humans; MAP Kinase Kinase 4; MicroRNAs; Myosin Heavy Chains; Nasopharyngeal Carcinoma; RNA, Viral; Signal Transduction; Stem Cells | 2019 |